Brief: Lyra Therapeutics Says Topline Results From ENLIGHTEN 2 Expected In Q2 2025
15/10/2024 12:13
Oct 15 (Reuters) - Lyra Therapeutics Inc LYRA.O :
* LYRA THERAPEUTICS FULLY ENROLLS PIVOTAL PHASE 3 ENLIGHTEN
2
TRIAL OF LYR-210 FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS
* LYRA THERAPEUTICS INC - TOPLINE RESULTS FROM ENLIGHTEN 2
EXPECTED IN Q2 2025
Source text for Eikon: ID:nGNX7QS3xP
Further company coverage: LYRA.O
((Reuters.Briefs@thomsonreuters.com;))